Denosumab for the treatment of osteoporosis
Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of denosumab with several thousand patients being followed for up to 10 years. Combined w...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-03-01
|
| Series: | Osteoporosis and Sarcopenia |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405525517300043 |